SLDB (Solid Biosciences) Institutional Ownership: 101.67% (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLDB Solid Biosciences Inc SLDB
34 GF Score
Price $9.07
! 2 Warning Signs
View Full Analysis

What is Solid Biosciences Institutional Ownership?

Solid Biosciences SLDB +2.26% 34 Institutional Ownership is 101.67% as of Aug. 13, 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Solid Biosciences's institutional ownership is 101.67%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Solid Biosciences's Insider Ownership is 8.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Solid Biosciences's Float Percentage Of Total Shares Outstanding is 87.99%.

Solid Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Solid Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solid Biosciences Institutional Ownership Chart

Solid Biosciences Historical Data

The historical data trend for Solid Biosciences can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 19.68 22.52 22.81 23.09 25.75 28.21 31.24 32.11 32.14 31.96
SLDB
34GF Score
Solid Biosciences Inc SLDB
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solid Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 101.67% mean?
Solid Biosciences (SLDB) has a Institutional Ownership of 101.67% as of Aug. 13, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Solid Biosciences and its competitors.
Is Solid Biosciences' Institutional Ownership too high?
Solid Biosciences' current Institutional Ownership is 101.67%. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' Institutional Ownership compare to MNPR and DSGN?
Solid Biosciences' Institutional Ownership of 101.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Solid Biosciences and its competitors. Solid Biosciences's current Institutional Ownership is 101.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current Institutional Ownership of 101.67%. The current Institutional Ownership is 101.67%. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current Institutional Ownership is 101.67% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solid Biosciences Business Description

Address 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score

Get the complete analysis for SLDB

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.07
Price